Bevespi Aerosphere

  • Asthma/COPD

Bevespi Aerosphere Generic Name & Formulations

General Description

Glycopyrrolate 9mcg, formoterol fumarate 4.8mcg; per inhalation; metered-dose inhaler.

Pharmacological Class

Anticholinergic + long-acting beta-2 agonist (LABA).

How Supplied

Inhalation aerosol—10.7g (120 inh)

Generic Availability


Bevespi Aerosphere Indications


Maintenance treatment of COPD.

Limitations of Use

Not indicated for relief of acute bronchospasm or for treatment of asthma.

Bevespi Aerosphere Dosage and Administration


2 inhalations twice daily (in the AM + PM). Max 2 inhalations twice daily.


Not established.

Bevespi Aerosphere Contraindications


Use of LABA without inhaled corticosteroid (ICS) in asthma.

Bevespi Aerosphere Boxed Warnings

Not Applicable

Bevespi Aerosphere Warnings/Precautions


LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in acute deteriorating COPD. Not for relief of acute symptoms. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasms or hypersensitivity reactions occur; use alternative therapy. Cardiovascular disorders (eg, coronary insufficiency, cardiac arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Hepatic disease; monitor. Severe renal impairment or ESRD requiring dialysis. Pregnancy. Labor & delivery. Nursing mothers.

Bevespi Aerosphere Pharmacokinetics

See Literature

Bevespi Aerosphere Interactions


Caution with concomitant other adrenergic drugs; may potentiate sympathetic effects. Concomitant xanthine derivatives, steroids, or diuretics may potentiate hypokalemia. Caution with non-K+-sparing diuretics. Extreme caution with MAOIs, tricyclics, or others that prolong QTc interval. Antagonized by β-blockers; if needed, use cardioselective agents if no acceptable alternatives. Additive effects with concomitant other anticholinergic-containing drugs; avoid.

Bevespi Aerosphere Adverse Reactions

Adverse Reactions

UTI, cough; paradoxical bronchospasm, hypersensitivity reactions, cardiovascular effects.

Bevespi Aerosphere Clinical Trials

See Literature

Bevespi Aerosphere Note

Not Applicable

Bevespi Aerosphere Patient Counseling

See Literature